Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001,
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …
The clinical and economic burden of chronic obstructive pulmonary disease in the USA
AJ Guarascio, SM Ray, CK Finch… - … and Outcomes Research, 2013 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in
the USA. In 2010, the cost of COPD in the USA was projected to be approximately US …
the USA. In 2010, the cost of COPD in the USA was projected to be approximately US …
Once-daily single-inhaler triple versus dual therapy in patients with COPD
DA Lipson, F Barnhart, N Brealey… - … England Journal of …, 2018 - Mass Medical Soc
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary
CF Vogelmeier, GJ Criner, FJ Martinez… - American journal of …, 2017 - atsjournals.org
This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline
Background: This document provides clinical recommendations for the pharmacologic
treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative …
treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative …
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel …
J Vestbo, A Papi, M Corradi, V Blazhko, I Montagna… - The Lancet, 2017 - thelancet.com
Background Limited data are available for the efficacy of triple therapy with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind …
D Singh, A Papi, M Corradi, I Pavlišová, I Montagna… - The Lancet, 2016 - thelancet.com
Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
Azithromycin for prevention of exacerbations of COPD
RK Albert, J Connett, WC Bailey… - … England Journal of …, 2011 - Mass Medical Soc
Background Acute exacerbations adversely affect patients with chronic obstructive
pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of …
pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of …
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American …
A Qaseem, TJ Wilt, SE Weinberger… - Annals of internal …, 2011 - acpjournals.org
Description: This guideline is an official statement of the American College of Physicians
(ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ATS) …
(ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ATS) …
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre …
FJ Martinez, PMA Calverley, UM Goehring, M Brose… - The Lancet, 2015 - thelancet.com
Background Roflumilast reduces exacerbations in patients with severe chronic obstructive
pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids …
pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids …